Overview
Alomone Labs is pleased to offer the TRPM Channel Antibody Explorer Kit (#AK-210). This Explorer Kit includes antibodies directed against TRPM channels.
Compounds
| Product Name | Cat # | Size |
|---|---|---|
Anti-Human TRPM1 Antibody |
ACC-041 | 1 x 50 µl |
Human TRPM1 Blocking Peptide |
BLP-CC041 | 1 x 40 µg |
Anti-TRPM2 Antibody |
ACC-043 | 1 x 50 µl |
TRPM2 Blocking Peptide |
BLP-CC043 | 1 x 40 µg |
Anti-TRPM3 (extracellular) Antibody |
ACC-050 | 1 x 50 µl |
TRPM3 (extracellular) Blocking Peptide |
BLP-CC050 | 1 x 40 µg |
Anti-TRPM4 Antibody |
ACC-044 | 1 x 50 µl |
TRPM4 Blocking Peptide |
BLP-CC044 | 1 x 40 µg |
Anti-TRPM5 Antibody |
ACC-045 | 1 x 50 µl |
TRPM5 Blocking Peptide |
BLP-CC045 | 1 x 40 µg |
Anti-TRPM6 (extracellular) Antibody |
ACC-046 | 1 x 50 µl |
TRPM6 (extracellular) Blocking Peptide |
BLP-CC046 | 1 x 40 µg |
Anti-TRPM7 Antibody |
ACC-047 | 1 x 50 µl |
TRPM7 Blocking Peptide |
BLP-CC047 | 1 x 40 µg |
Anti-TRPM8 (extracellular) Antibody |
ACC-049 | 1 x 50 µl |
TRPM8 (extracellular) Blocking Peptide |
BLP-CC049 | 1 x 40 µg |
Scientific Background
TRP channels are a large family (about 28 genes) of plasma membrane, non-selective cationic channels that are either specifically or ubiquitously expressed in excitable and non-excitable cells.1 The TRP channels have putative six-transmembrane domains (TM) with a pore domain between the fifth and the six TM, and all assemble as tetramers. Both the N- and the C-terminus of all TRPs are intracellular.3
According to IUPHAR the TRP family comprises of three main subfamilies on the basis of sequence homology; TRPC (canonical), TRPV (vanilloid) and TRPM (melastatin). To date, three extra subfamilies are also considered to belong to the TRP family; the TRPA, TRPML, and the TRPP.1-4
The TRPM subfamily consists of eight members, TRPM1 to TRPM8, which also can be further subdivided into four subgroups based on their sequence homology: (1)TRPM1 and TRPM3 (2) TRPM6 and TRPM7 (3) TRPM4 and TRPM5 (4) TRPM2 and TRPM8.5
- Montell, C. et al. (2002) Mol. Cell. 9, 229.
- Clapham, D.E. (2003) Nature 426, 517.
- Moran, M.M. et al. (2004) Curr.Opin.Neurobiol. 14, 362.
- Clapham, D.E. et al. (2003) Pharmacol. Rev. 55, 591.
- Harteneck, C. (2005) Naunyn Schmiedebergs Arch Pharmacol. 371, 307.
